Showing results (71-80 of 132) with videos related to
Sort By:
Pageof 14
Diagnostic Microbiology and Infectious Disease|October 9, 2007
WITHDRAWN: Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenemRonald N Jones, Helio S Sader, Thomas R Fritsche, et al.Diagnostic Microbiology and Infectious Disease|November 16, 2004
Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwideHelio S Sader, Jennifer M Streit, Thomas R Fritsche, et al.Diagnostic Microbiology and Infectious Disease|May 3, 2006
Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)Michael A Pfaller, Helio S Sader, Thomas R Fritsche, et al.Diagnostic Microbiology and Infectious Disease|April 25, 2006
Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA)Paul R Rhomberg, Thomas R Fritsche, Helio S Sader, et al.Journal of Clinical Microbiology|August 8, 2006
Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organismsThomas R Fritsche, Robert P Rennie, Beth P Goldstein, et al.The Journal of Antimicrobial Chemotherapy|March 4, 2008
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infectionsThomas R Fritsche, Paul R Rhomberg, Helio S Sader, et al.BMC Infectious Diseases|April 20, 2007
Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)Helio S Sader, Amy A Watters, Thomas R Fritsche, et al.Clinical Medicine & Research|September 1, 2018
Infectious Mononucleosis and Lyme Disease as Confounding Diagnoses: A Report of 2 CasesTrever M Koester, Jennifer K Meece, Thomas R Fritsche, et al.International Journal of Antimicrobial Agents|October 26, 2007
Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infectionsHelio S Sader, Rajiv Mallick, Andreas Kuznik, et al.Antimicrobial Agents and Chemotherapy|July 29, 2005
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strainsHelio S Sader, Thomas R Fritsche, Koné Kaniga, et al.Pageof 14